Efficacy and safety of posaconazole and liposomal amphotericin B use for prophylaxis of invasive fungal infections in a paediatric and young adult haemato-oncological population
Posaconazole was associated with fewer adverse events than L-AmB, and both drugs showed similar efficacy in preventing IFI breakthroughs, making posaconazole a viable alternative for primary prophylaxis.
Authors
- Giulia Reggiani (ORCID: https://orcid.org/0000-0002-9479-6366)
- Elisa Barbieri (ORCID: https://orcid.org/0000-0003-0850-8784)
- Alessandra Biffi (ORCID: https://orcid.org/0000-0002-4610-0870)
- Daniele Donà (ORCID: https://orcid.org/0000-0001-7105-2105)
- Luca Dell’Anna (ORCID: https://orcid.org/0000-0002-2012-1681)
- Cecilia Liberati (ORCID: https://orcid.org/0000-0002-0821-5757)
- Carlo Giaquinto (ORCID: https://orcid.org/0000-0001-9365-0413)
- Antonio Marzollo (ORCID: https://orcid.org/0000-0003-2177-8500)
- Marica De Pieri
- Grazia Maria Virzì (ORCID: https://orcid.org/0000-0001-7934-9800)
- Lorenzo Chiusaroli (ORCID: https://orcid.org/0009-0001-9633-873X)
- Maria Gabelli (ORCID: https://orcid.org/0000-0002-6226-9895)
- Daniele Mengato (ORCID: https://orcid.org/0000-0003-1374-1505)
Institutions
- University of Padua (IT)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-01-10
- DOI
- https://doi.org/10.1093/jac/dkae479
- Citations
- 6
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 8.38